Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F20%3A00074013" target="_blank" >RIV/65269705:_____/20:00074013 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/20:10427560
Result on the web
<a href="https://journals.lww.com/hemasphere/Fulltext/2020/12000/Ropeginterferon_Alfa_2b__Efficacy_and_Safety_in.3.aspx" target="_blank" >https://journals.lww.com/hemasphere/Fulltext/2020/12000/Ropeginterferon_Alfa_2b__Efficacy_and_Safety_in.3.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/HS9.0000000000000485" target="_blank" >10.1097/HS9.0000000000000485</a>

Result language
angličtina
Original language name
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
Original language description
Ropeginterferon (Besremi(R)) is a novel mono-pegylated IFNa-2b with reduced dosing frequency and improved tolerability compared to other pegylated IFNs, and is approved in Europe as first-line therapy for treatment of PV in patients of all ages.10,13 Here we report the efficacy and safety after 24 months of ropeginterferon treatment compared to HU in the PROUD-PV/CONTINUATION-PV phase III trials (EudraCT: 2012-005259-18; 2014-001357-17), analyzed post-hoc in two age cohorts (<60 years and GREATER-THAN OR EQUAL TO60 years) in PV patients aiming to evaluate the benefit-risk ratio of ropeginterferon therapy in the elderly.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)